Primary-outcome gap shrinks after first year; increased valve thrombosis noted in TAVR arm between years 1 and 2

Patients at low surgical risk for mortality who underwent transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve continued to show significantly better outcomes at 2 years than those who underwent surgical aortic valve replacement (SAVR), but the differences between the two groups began to narrow from year 1 to year 2, according to late-breaking trial results presented Sunday at the American College of Cardiology (ACC) Scientific Sessions 2020 virtual conference.